Allogeneic HSCT Recipients Have Increased Risk for Skin Cancer

Share this content:
Allogeneic hematopoietic stem-cell transplant recipients have an increased risk for developing skin cancer.
Allogeneic hematopoietic stem-cell transplant recipients have an increased risk for developing skin cancer.

Allogeneic hematopoietic stem-cell transplant (HSCT) recipients have an increased risk for developing basal cell carcinoma, squamous cell carcinoma, and malignant melanoma, a new study published online ahead of print in JAMA Dermatology has shown.1

Although the risk of nonmelanoma skin cancer is well recognized in patients who have undergone solid-organ transplant, there are limited data on the risk of cancer in HSCT recipients.

Therefore, researchers sought to evaluate the risk of cutaneous cancer in HSCT recipients compared with that of renal transplant recipients and those who have not undergone any transplant.

For the study, researchers analyzed data from 3,302 HSCT recipients (1,007 allogeneic, 2,295 autologous), 4,789 renal transplant recipients, and 10 matched nontransplanted individuals for each of the groups from the general population.

Results showed that allogeneic HSCT recipients had an increased risk of basal cell carcinoma (HR=3.1; 95% CI: 1.0 – 5.2), squamous cell carcinoma (HR=18.3; 95% CI: 4.1 – 81.8), and malignant melanoma (HR=5.5; 95% CI: 1.7 – 17.7) compared with the general population.

Researchers found that allogeneic HSCT recipients also had a 3-fold higher risk of malignant melanoma compared with renal transplant recipients, while the risk of basal cell carcinoma was only increased in allogeneic HSCT recipients conditioned with total-body irradiation (HR=3.9; 95% CI: 2.6 – 6.8).

RELATED: Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients

On the other hand, the risk of basal cell carcinoma was similar among allogeneic HSCT and renal transplant recipients and the risk of squamous cell carcomina was highest among renal transplant recipients.

The study demonstrated no elevated risk for skin cancer among autologous HSCT recipients.

“Our findings indicate the relevance of dermatologic follow-up in HSCT recipients,” the authors concluded. “Furthermore, studies examining prognosis of skin cancer in HSCT recipients are needed.”

Reference

  1. Omland SH, Gniadecki R, Hædersdal M, et al. Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study [published online ahead of print October 10, 2015]. JAMA Dermatol. doi: 10.1001.jamadermatol.2015.3902.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters